Piramel Alzheimer's imaging agent gets EU thumbs up
This article was originally published in Clinica
Executive Summary
The EU's CHMP last week granted a positive opinion to marketing for another imaging agent for use in Alzheimer's disease, Piramal Imaging's NeuraCeq (florbetaben). It gave the go-ahead for Lilly and Avid Radiopharmaceuticals' Amyvid (florbetapir F 18 injection in October 2012, which was then the first imaging agent of its kind to be approved in the EU in January this year; Amyvid was approved in the US earlier in April that year. GE Healthcare's similar product Vizamyl (18F flutemetamol) recently received US approval.